BioConnection announces that it is collaborating with AdaptVac for the Drug Product manufacture of their COVID-19 vaccine in its state-of-the-art-GMP manufacturing facility in the Netherlands. AdaptVac aims to accelerate the development of safe and efficacious therapeutic and prophylactic vaccines to treat and prevent specific cancers, infectious diseases and immunological disorders. AdaptVac with its capsid Virus-Like Particle (cVLP) technology could provide a solution to protect against new Covid-19 infections in the still evolving pandemic.<\/p>\n\n\n\n
\u201cWe strongly believe that our capsid Virus-Like Particle display technology will be a key player in global emergencies, such as the COVID-19 epidemic, and have selected BioConnection as our trusted partner in the Drug Product manufacture of our vaccine. We are grateful to BioConnection for ensuring vaccine production can happen in the fastest possible timeline with the expected quality,\u201d says Wian de Jongh, AdaptVac\u2019s CEO.<\/p>\n\n\n\n
\u201cThe urgency level to develop an effective vaccine to combat COVID-19 could not be higher,\u201d says BioConnection CEO Alexander Willemse. \u201cWe are delighted that we are able to contribute to a vaccine which could protect against new COVID-19 infections\u201d<\/p>\n\n\n\n